Free Trial
NYSE:BAX

Baxter International (BAX) Stock Price, News & Analysis

$39.10
-0.27 (-0.69%)
(As of 12:12 PM ET)

About Baxter International Stock (NYSE:BAX)

Key Stats

Today's Range
$39.05
$39.70
50-Day Range
$33.97
$40.26
52-Week Range
$31.01
$44.01
Volume
841,271 shs
Average Volume
4.16 million shs
Market Capitalization
$19.92 billion
P/E Ratio
7.52
Dividend Yield
2.97%
Price Target
$41.73
Consensus Rating
Hold

Company Overview

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Baxter International Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 89th Percentile

Baxter International scored higher than 89% of companies evaluated by MarketBeat, and ranked 134th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Baxter International has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 2 buy ratings, 8 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Baxter International has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Baxter International's stock forecast and price target.
  • Earnings Growth

    Earnings for Baxter International are expected to grow by 8.11% in the coming year, from $2.96 to $3.20 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Baxter International is 7.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.51.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Baxter International is 7.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.31.

  • Price to Earnings Growth Ratio

    Baxter International has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Baxter International has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Baxter International's valuation and earnings.
  • Percentage of Shares Shorted

    2.14% of the outstanding shares of Baxter International have been sold short.
  • Short Interest Ratio / Days to Cover

    Baxter International has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Baxter International has recently increased by 24.60%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Baxter International pays a meaningful dividend of 2.95%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Baxter International does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Baxter International is 22.31%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Baxter International will have a dividend payout ratio of 36.25% next year. This indicates that Baxter International will be able to sustain or increase its dividend.

  • Read more about Baxter International's dividend.
  • Percentage of Shares Shorted

    2.14% of the outstanding shares of Baxter International have been sold short.
  • Short Interest Ratio / Days to Cover

    Baxter International has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Baxter International has recently increased by 24.60%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Baxter International has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Baxter International this week, compared to 7 articles on an average week.
  • Search Interest

    Only 13 people have searched for BAX on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Baxter International to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Baxter International insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.21% of the stock of Baxter International is held by insiders.

  • Percentage Held by Institutions

    90.19% of the stock of Baxter International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Baxter International's insider trading history.

BAX Stock News Headlines

5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Baxter International (NYSE:BAX) Upgraded at StockNews.com
China Stockpiling Gold “Like No Tomorrow”
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
StockNews.com Downgrades Baxter International (NYSE:BAX) to Hold
See More Headlines

BAX Stock Analysis - Frequently Asked Questions

Baxter International's stock was trading at $38.66 at the beginning of 2024. Since then, BAX shares have increased by 2.3% and is now trading at $39.54.
View the best growth stocks for 2024 here
.

Baxter International Inc. (NYSE:BAX) posted its earnings results on Tuesday, August, 6th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.02. Baxter International's revenue was up 2.8% on a year-over-year basis.
Read the conference call transcript
.

Baxter International subsidiaries include Cheetah Medical, ApaTech Limited, Baxter AO, Baxter Belgium SPRL, Baxter (China) Investment Co. Ltd, Baxter Company Ltd, Baxter Corporation (Canada), and more.

Baxter International's top institutional shareholders include Bank of New York Mellon Corp (1.33%), LSV Asset Management (0.82%), Shapiro Capital Management LLC (0.64%) and Thompson Siegel & Walmsley LLC (0.39%). Insiders that own company stock include Jeanne K Mason, Albert P L Stroucken, Jacqueline Kunzler and Brian Stevens.
View institutional ownership trends
.

Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Baxter International investors own include Xtrackers California Municipal Bond ETF (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC) and Abbott Laboratories (ABT).

Company Calendar

Ex-Dividend for 7/1 Dividend
5/31/2024
Dividend Payable
7/01/2024
Last Earnings
8/06/2024
Ex-Dividend for 10/1 Dividend
8/30/2024
Today
9/19/2024
Dividend Payable
10/01/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
07181310
Employees
60,000
Year Founded
1931

Price Target and Rating

Average Stock Price Target
$41.73
High Stock Price Target
$54.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+6.7%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$2.66 billion
Pretax Margin
-0.50%

Debt

Sales & Book Value

Annual Sales
$15.00 billion
Cash Flow
$5.22 per share
Book Value
$16.69 per share

Miscellaneous

Free Float
508,510,000
Market Cap
$19.92 billion
Optionable
Optionable
Beta
0.59

Social Links

Should I Buy Baxter International Stock? BAX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 8, 2024. Please send any questions or comments about these Baxter International pros and cons to contact@marketbeat.com.

Baxter International
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Baxter International Inc.:

  • Baxter International Inc. has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
  • The company's dividend yield of 3.06% provides investors with a steady income stream, making it an attractive option for income-oriented investors.
  • Recent upgrades in stock ratings from "hold" to "buy" by reputable sources like StockNews.com could signal positive momentum and potential stock price appreciation.
  • Baxter International Inc.'s current stock price of $36.91 presents a potential buying opportunity for investors looking to enter at a relatively lower price point.
  • The company's diversified portfolio of healthcare products across different segments provides stability and resilience in varying market conditions.

Baxter International
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Baxter International Inc. for these reasons:

  • Analysts have downgraded Baxter International Inc.'s stock rating to "underweight," indicating potential concerns about the company's future performance.
  • The company's stock has experienced a recent decline of 0.6%, suggesting short-term volatility and potential risks for investors.
  • With a debt-to-equity ratio of 1.35, Baxter International Inc. carries a moderate level of debt, which could impact its financial flexibility and risk profile.
  • Despite positive earnings results, the company's stock price has not shown significant growth, raising questions about its ability to deliver strong returns to investors.
  • Market analysts have set a consensus target price of $41.73 for Baxter International Inc.'s stock, indicating limited upside potential based on current valuations.

This page (NYSE:BAX) was last updated on 9/19/2024 by MarketBeat.com Staff
From Our Partners